Search

Your search keyword '"Hansen, Birgitte V."' showing total 18 results
Start Over Author "Hansen, Birgitte V."
18 results on '"Hansen, Birgitte V."'

2. Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomized, double blind trial

Author

Lund, Soren S., Tarnow, Lise, Frandsen, Merete, Nielsen, Bente B., Hansen, Birgitte V., Pedersen, Oluf, Parving, Hans-Henrik, and Vaag, Allan A.

Subjects
Metformin -- Comparative analysis, Metformin -- Usage, Repaglinide -- Usage, Repaglinide -- Comparative analysis, Type 2 diabetes -- Care and treatment, Weight gain -- Prevention
Published
2009

10. Fish Oil in Diabetic Nephropathy

Author

Rossing, Peter, Hansen, Birgitte V., Nielsen, Flemming S., Myrup, Bjarne, Holmer, Gunhild, and Parving, Hans-Henrik

Published
1996

13. Lack of relationship between an insertion/deletion polymorphism in the angiotensin I-converting enzyme gene and diabetic nephropathy and proliferative retinopathy in IDDM patients

Author

Tarnow, Lise, Cambien, Francois, Rossing, Peter, Nielsen, Flemming S., Hansen, Birgitte V., Lecerf, Laure, Poirier, Odette, Danilov, Sergei, and Parving, Hans-Henrik

Subjects
Type 1 diabetes -- Genetic aspects -- Risk factors, Diabetic nephropathies -- Risk factors -- Genetic aspects, Health, Genetic aspects, Risk factors
Abstract

Genotypic abnornmalities of the renin-angiotensin system have been suggested as a risk factor for the development of diabetic nephropathy and proliferative retinopathy. We studied the relationship between an insertion(I)/deletion (D) [...]

Published
1995

14. Low birth rate: a risk factor for development of diabetic nephropathy?

Author

Rossing, Peter, Tarnow, Lise, Nielsen, Flemming S., Hansen, Birgitte V., Brenner, Barry M., and Parving, Hans-Henrik

Subjects
Birth weight, Low -- Health aspects, Diabetic nephropathies -- Risk factors, Health, Risk factors, Health aspects
Abstract

It has been demonstrated that intrauterine growth retardation, defined as birth weight below the 10th percentile, gives rise to a reduction in nephron number. Oligonephropathy has been suggested to increase [...]

Published
1995

18. Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial.

Author

Lund SS, Tarnow L, Frandsen M, Nielsen BB, Hansen BV, Pedersen O, Parving HH, and Vaag AA

Subjects
Blood Glucose metabolism, Carbamates adverse effects, Double-Blind Method, Drug Therapy, Combination, Female, Glycated Hemoglobin adverse effects, Glycated Hemoglobin metabolism, Humans, Hypoglycemia chemically induced, Hypoglycemia prevention & control, Hypoglycemic Agents adverse effects, Insulin administration & dosage, Insulin adverse effects, Insulin Aspart, Male, Metformin adverse effects, Middle Aged, Patient Compliance, Piperidines adverse effects, Treatment Outcome, Weight Gain, Carbamates administration & dosage, Diabetes Mellitus, Type 2 drug therapy, Hypoglycemic Agents administration & dosage, Insulin analogs & derivatives, Metformin administration & dosage, Piperidines administration & dosage
Abstract

Objectives: To study the effect of insulin treatment in combination with metformin or an insulin secretagogue, repaglinide, on glycaemic regulation in non-obese patients with type 2 diabetes., Design: Randomised, double blind, double dummy, parallel trial., Setting: Secondary care in Denmark between 2003 and 2006., Participants: Non-obese patients (BMI

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results